Okawa T, Kita M
Dept. of Radiology, Tokyo Women's Medical College.
Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2659-63.
Intra-arterial infusion chemotherapy has become widely accepted in the multimodal treatment of many malignant tumors. We have used Port-A-Cath, which is an implantable drug delivery system, for regional infusion therapy in cancer chemotherapy since April 1984 and made a study protocol for evaluation of safety, usefulness and reliability. Twenty-two patients with pancreatic and intra-pelvic tumors have been treated with this method. Drugs of this series were adriamycin and mitomycin-C, using intermittently and 5-Fluorouracil continuously with or without radiotherapy. In localized unresectable adenocarcinoma of pancreas, the median implanted days of Port-A-Cath was 139 days and the median survival from implantation was 212 days. On the other hand, in advanced or recurrent intra-pelvic tumors, the median implanted day was 274 days and median survival time from implantation was 583 days. One case developed skin necrosis at the implanted area, and three had infections which were able to be managed. The findings suggest that Port-A-Cath assures safety and good quality of life in cancer patients because of the freedom of movement, normal physical appearance and barriers to infection due to subcutaneous placement.
动脉内灌注化疗已在多种恶性肿瘤的多模式治疗中得到广泛认可。自1984年4月以来，我们使用可植入式给药系统Port-A-Cath进行癌症化疗的区域灌注治疗，并制定了一项评估安全性、有效性和可靠性的研究方案。22例胰腺和盆腔内肿瘤患者接受了该方法治疗。该系列药物为阿霉素和丝裂霉素-C，间歇性使用，5-氟尿嘧啶持续使用，联合或不联合放疗。在局部不可切除的胰腺腺癌中，Port-A-Cath的中位植入天数为139天，植入后的中位生存期为212天。另一方面，在晚期或复发性盆腔内肿瘤中，中位植入天数为274天，植入后的中位生存时间为583天。1例患者植入区域出现皮肤坏死，3例发生感染，但均得到控制。研究结果表明，Port-A-Cath因患者活动自如、外观正常以及皮下放置可防止感染，从而确保了癌症患者的安全性和良好生活质量。
